Skip to main content

Specialty Pharmacy

  • AARP highlights rising specialty prices as FDA looks to tackle development costs, speed

    The price of drugs — particularly specialty drugs — is the perennial issue plaguing both patients and the companies that make them, as the cost of making a drug, estimated at around $2.6 billion with an average time of 10-15 years, will be factored into the cost of a treatment. Recently, though, patient advocates and regulators have begun acknowledging a need for something to be done about this trend.

  • Teva names new president, CEO

    JERUSALEM — Teva has a named its next leader. The company on Monday announced the appointment of Kåre Schultz as its president and CEO, who will take over the position from Dr. Yitzhak Peterburg.

  • Sanofi gets tentative FDA approval for Humalog follow-on Admelog
    SILVER SPRING, Md. — The Food and Drug Administration recently granted tentative approval to Sanofi’s Admelog (insulin lispro injection, 100 units/ml), a rapid-acting human insulin analog. The drug, a follow-on biologic version of Lilly’s Humalog, is indicated to improve glycemic control in patients with diabetes. 
     
    The approval means that Admelog has met all requirements for the regulatory agency, pending any patent issues that have not yet been resolved. 
     

  • Value Drug acquires specialty pharmacy Restore Rx

    DUNCANSVILLE, Pa. — Value Drug, through its Value Specialty Pharmacy subsidiary, will be acquiring Brunswick, Tenn.-based specialty pharmacy Restore Rx, the company announced this week.

    With the acquisition, the company said it would expand the scope of Value Specialty Pharmacy’s business while retaining the current location, leadership and employees of Restore Rx. The acquisition brings Value Drug a nationwide patient footprint and headquarters in close proximity to the FedEx hub in Memphis, facilitating expedited shipping.

  • Walgreens helps underwrite CDC Foundation's HIV research

    DEERFIELD, Ill. — Following last year’s impactful collaboration between Walgreens and the CDC Foundation addressing the Zika outbreak, the two organizations on Wednesday announced they are once again working together to help address another public health challenge — this time HIV prevention.

  • J.D. Power: Overall pharmacy satisfaction dips amid drug price concerns

    COSTA MESA, Calif. — J.D Power’s 2017 U.S. Pharmacy Study is showing a drop in overall customer satisfaction for an industry that typically ranks among the highest-scoring ones assessed by the market research company.

  • Gilead to acquire Kite Pharma

    FOSTER CITY and SANTA MONICA, Calif. — In a deal estimated at roughly $11.9 billion, Gilead Sciences will be acquiring leading cell therapy company Kite Pharma for $180 per share, the companies announced last week. Among the potential treatments Gilead will acquire is Kite’s most advanced therapy candidate, axicaabtagene ciloleucel (axi-cel), a cancer-fighting therapy expected to be the first to market to treat refractory aggressive non-Hodgkin lymphoma, with a decision date of Nov. 29.

  • FDA approves first-ever gene therapy treatment for acute lymphoblastic leukemia

    SILVER SPRING, Md. — The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases.

    The FDA approved Novartis' Kymriah (tisagenlecleucel) for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia. Kymriah is the first therapy based on gene transfer approved by the FDA.

X
This ad will auto-close in 10 seconds